Hormonal
Genetically proxied GIPR agonist reduces the risk of 14 cardiometabolic diseases, including obesity, hypertension, and coronary heart disease, with effects on angina and myocardial infarction partially mediated by the inflammatory biomarker Flt3L.
Genetic evidence supports that activating the GIP receptor reduces the risk of major cardiometabolic diseases, including obesity, hypertension, and heart conditions. This benefit is partly achieved by lowering levels of the inflammatory protein Flt3L, which is linked to angina and heart attacks. This suggests GIP-targeting therapies could offer broader heart health benefits beyond blood sugar control.
The genetic mimicry of GIPR enhancement showed significant protective associations with 14 CMDs... Mediation analysis revealed that Fms-related tyrosine kinase 3 ligand (Flt3L) partially mediated the effects of GIPR agonist on angina... and myocardial infarction(MI)... accounting for 15.49% and 16.71% of the total risk reduction, respectively.
Why this rating
Uses Mendelian Randomization with large sample sizes and robust sensitivity analyses, though it relies on genetic proxies rather than direct clinical trials.
Source
Decoding the impact of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist on cardiometabolic health: inflammatory mediators at the focus
Fang Cheng et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-01744-2
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →